PFE Stock Price Today Per Share: Is Pfizer a Buy at $43?

Pfizer (NYSE: PFE) stock is up 2.3% today, trading at $43.04 per share. The stock has been on a tear in recent months, as investors cheer the company's progress in developing and distributing a COVID-19 vaccine.

Pfizer's COVID-19 Vaccine

The company's vaccine, developed in partnership with BioNTech, was one of the first to be approved for use in the United States. The vaccine has been shown to be safe and effective, and it is expected to play a major role in the fight against the pandemic.

Pfizer has already delivered millions of doses of its vaccine around the world, and it is expected to continue to ramp up production in the coming months. The company has said that it expects to produce up to 2 billion doses of the vaccine in 2021.

Pfizer's Other Businesses

In addition to its COVID-19 vaccine, Pfizer has a number of other businesses that are also performing well. The company's oncology business, which sells cancer drugs, is growing rapidly. Pfizer also has a strong presence in the generics market, and it is expected to benefit from the increasing demand for generic drugs in the coming years.

Pfizer's Financial Results

Pfizer's financial results have been strong in recent years. In 2020, the company reported revenue of $41.9 billion, up 2% from the previous year. Net income was $9.6 billion, up 6% from 2019.

Pfizer is expected to continue to perform well in the coming years. The company's COVID-19 vaccine is expected to be a major driver of growth, and the company's other businesses are also expected to continue to perform well.

Is Pfizer a Buy?

Pfizer stock is trading at a forward price-to-earnings ratio of 12.3, which is below the average for the pharmaceutical industry. The stock is also trading at a discount to its historical price-to-earnings ratio.

Given its strong fundamentals and attractive valuation, Pfizer stock is a buy for investors. The company is expected to continue to perform well in the coming years, and the stock is trading at a discount to its fair value.

Table 1: Pfizer's Financial Results

Table 2: Pfizer's Stock Price

Table 3: Pfizer's Forward Price-to-Earnings Ratio

Table 4: Pfizer's Historical Price-to-Earnings Ratio

Key Takeaways

• Pfizer's COVID-19 vaccine is expected to be a major driver of growth in the coming years.
• Pfizer's other businesses are also performing well.
• Pfizer's financial results have been strong in recent years.
• Pfizer stock is trading at a forward price-to-earnings ratio of 12.3, which is below the average for the pharmaceutical industry.
• Pfizer stock is trading at a discount to its historical price-to-earnings ratio.
• Given its strong fundamentals and attractive valuation, Pfizer stock is a buy for investors.